Growth Hormone and Obesity

• Autores: Astrid Hjelholt, Morten Høgild, Ann Mosegaard Bak, Mai Christiansen Arlien Søborg, Amanda Bæk, Niels Jessen, Bjørn Richelsen, Steen Bønløkke Pedersen, Niels Møller, Jens Otto Lunde Jørgensen
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 49, Nº. 2, 2020 (Ejemplar dedicado a: Obesity), págs. 239-250
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Growth hormone (GH) exerts IGF-I dependent protein anabolic and direct lipolytic effects. Obesity reversibly suppresses GH secretion driven by elevated FFA levels, whereas serum IGF-I levels remain normal or elevated due to elevated portal insulin levels. Fasting in lean individuals suppresses hepatic IGF-I production and increases pituitary GH release, but this pattern is less pronounced in obesity. Fasting in obesity is associated with increased sensitivity to the insulin-antagonistic effects of GH. GH treatment in obesity induces a moderate reduction in fat mass and an increase in lean body mass but the therapeutic potential is uncertain.